Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Nomura Holdings Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15 (market cap $2.81B), while Nomura Holdings Inc trades at $9.2 (market cap $27.06B). The key difference: Nomura Holdings Inc is far larger — about 9.6× Dyne Therapeutics Inc. Common Stock's market cap, and Nomura Holdings Inc pays a 3.5% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Nomura Holdings Inc for 56 Days on average.
| DYN | NMR | |
|---|---|---|
Market Cap | $2.81B | $27.06B |
Volume | 2,195,902 | 725,769 |
Sector | Health | Financials |
52-Week High | $26.78 | $10.86 |
52-Week Low | $14.60 | $6.92 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $2.13B | $38.42T |
Dividend Yield | — | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Nomura Holdings (NMR) trades at $9.58, showing minimal daily movement with a slight 0.1% gain. The stock exhibits a bearish technical signal, trading near support at $9, while recent earnings show mixed quarterly performance with two misses and one beat against expectations. Revenue growth is strong, reaching $1.66 trillion in 2025 with a net income margin of 20.4%, supported by solid valuation ratios including a P/E of 11.37. Analyst sentiment is cautious with a hold-heavy consensus, though recent news highlights potential momentum and value opportunities.
The outlook for NMR is balanced between fundamental strength and near-term headwinds. Attractive valuations and robust profitability offer upside, but bearish technicals, inconsistent earnings beats, and rising debt-to-asset ratios pose risks. Investors should weigh the company's solid revenue trajectory against execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
